Cannabinoids and brain injury: Therapeutic implications

Trends in Molecular Medicine

Volumn 8, Issue 2, 2002, Pages 58-61

  Mechoulam, Raphael ^a   Panikashvili, David ^b   Shohami, Esther ^b  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

2 ARACHIDONOYLGLYCEROL; ANANDAMIDE; CANNABINOID; REACTIVE OXYGEN METABOLITE; TUMOR NECROSIS FACTOR ALPHA;

BRAIN INJURY; CYTOKINE PRODUCTION; DRUG MECHANISM; DRUG STRUCTURE; HUMAN; NEUROPROTECTION; NONHUMAN; REVIEW; SYNAPTIC TRANSMISSION;

EID: 0036156353     PISSN: 14714914     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1471-4914(02)02276-1     Document Type: Review

References (61)

1. Absence of evidence for the effectiveness of five interventions routinely used in the intensive care management of severe head injury: A systematic review
2. Lack of effect of induction of hypothermia after acute brain injury
3. Brain damage, sex hormones and recovery: A new role for progesterone and estrogen?
4. The role of excitotoxicity in neurodegenerative disease: Implications for therapy
5. Therapeutic effects of endothelin receptor antagonists in stroke
6. Endothelin levels increase in rat focal and global ischemia
7. Changes of endothelin-1 gene expression in rat brains during ischemia and ischemic reperfusion
8. Therapeutic potential of endothelin receptor antagonists in experimental stroke
9. Selective antagonism of endothelin-A receptors improves outcome in both head trauma and focal stroke
10. Biochemical, cellular and molecular mechanisms in the evolution of secondary damage after severe traumatic brain injury in infants and children: Lessons learned from the bedside
11. Melatonin as pharmacological agent against oxidative damage to lipids and DNA
12. Oxidative stress in closed head injury: Brain antioxidant capacity as an indicator of functional outcome
13. Reactive oxygen radicals in signaling and damage in the ischemic brain
14. A peptide derived from activity-dependent neuroprotective protein (ADNP) ameliorates injury response in closed head injury in mice
15. Endocannabinoids
16. Cannabinoid receptors and their endogenous agonist, anandamide
17. Pharmacology of cannabinoid receptor ligands
18. The neurobiology and evolution of cannabinoid signalling
19. Evidence for a new G protein-coupled cannabinoid receptor in mouse brain
20. Isolation and structure of a brain constituent that binds to the cannabinoid receptor
21. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors
22. 2-Arachidonoylglycerol: A possible endogenous cannabinoid receptor ligand in brain
23. 1 receptor
24. Pathways and mechanisms of N-acylethanolamine biosynthesis: Can anandamide be generated selectively?
25. Endocannabinoids: Endogenous cannabinoid receptor ligands with neuromodulatory action
26. The endocannabinoid system as a target for therapeutic drugs
27. The effects of cannabinoids on the brain
28. The endocannabinoid nervous system. Unique opportunities for therapeutic intervention
29. Cannabinoid receptors and the regulation of immune response
30. Endocannabinoids as cardiovascular modulators
31. Ligand-receptor signaling with endocannabinoids in preimplantation embryo development and implantation
32. Cannabinoid receptors and pain
33. SR141716A enhances spatial memory as assessed in a radial-arm maze task in rats
34. Cannabinoids inhibit the formation of new synapses between hippocampal neurons in culture
35. Leptin-regulated endocannabinoids are involved in maintaining food intake
36. Endogenous cannabinoids and appetite
37. Critical role of the endogenous cannabinoid system in mouse pup suckling and growth
38. Human brain capillary endothelium 2-arachidonylglycerol (endocannabinoid) interacts with endothelin-1
39. The endocannabinoid system: A physiological perspective on its role in psychomotor control
40. Cannabinoid receptors and immunity
41. N-acylated glycerophospholipids and their derivatives
42. Cannabinoid receptor agonists inhibit glutamatergic synaptic transmission in rat hippocampal cultures
43. Cannabinoid receptor agonists protect cultured rat hippocampal neurons from excitotoxicity
44. Dual effects of anandamide on NMDA receptor-mediated responses and neurotransmission
45. 1 cannabinoid receptor induction in experimental stroke
46. N-acylethanolamines and precursor phospholipids - Relation to cell injury
47. Formation of N-acylphosphatidylethanolamines and N-acetylethanolamines: Proposed role in neurotoxicity
48. Occurrence and postmortem generation of anandamide and other long-chain N-acylethanolamines in mammalian brain
49. Cannabinoids and neuroprotection in global and focal cerebral ischemia and in neuronal cultures
50. Endocannabinoids protect cerebral cortical neurons from in vitro ischemia in rats
51. 2-Arachidonylglycerol an endogenous cannabinoid, inhibits TNF-α production in murine macrophages, and in mice
52. 9-tetrahydrocannabinol, the main active compound in marijuana, against ouabain-induced in vivo excitotoxicity
53. Diffusion and perfusion MRI following closed head injury in rats
54. Anandamide, but not 2-arachidonylglycerol, accumulates during in vivo neurodegenration
55. An endogenous cannabinoid (2-AG) is neuroprotective after brain injury
56. Generation of 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand, in picrotoxinin-administered rat brain
57. Protection of rat brain by anandamide against neuronal injury
58. Dexanabinol (HU-211): A nonpsy-chotropic cannabinoid with neuroprotective properties
59. 9-tetrahydrocannabinol are neuroprotective antioxidant
60. Mechanisms of endocannabinoid inactivation: Biochemistry and pharmacology
61. Fatty acid amide hydrolase: Biochemistry, pharmacology, and therapeutic possibilities for an enzyme hydrolyzing anandamide, 2-arachidonoylglycerol, palmitoylethanol-amide, and oleamide